Cecerska-Heryć Elżbieta, Ronkowski Bartosz, Heryć Rafał, Serwin Natalia, Grygorcewicz Bartłomiej, Roszak Marta, Galant Katarzyna, Dołęgowska Barbara
Department of Laboratory Medicine, Pomeranian Medical University of Szczecin, Szczecin, Poland.
Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University of Szczecin, Szczecin, Poland.
Proteomics Clin Appl. 2023 Jan;17(1):e2200003. doi: 10.1002/prca.202200003. Epub 2022 Sep 6.
There is an increasing prevalence of inflammatory bowel disease (IBD) and to date, no effective treatment has been developed and the exact etiology of this disease remains unknown. Nevertheless, a growing number of proteomic and lipidomic studies have identified certain proteins and lipids which can be used successfully in patients to improve diagnoses and monitoring of treatment.
We have focused on the applications of proteins and lipids for IBD diagnostics, including differentiation of Crohn's disease (CD) and ulcerative colitis (UC), treatment monitoring, monitoring of clinical state, likelihood of relapse, and their potential for novel targeted treatments.
Analysis of protein and lipid profiles can: improve the availability and use of diagnostic markers; improve understanding of the pathomechanisms of IBD, for example, several studies have implicated platelet dysfunction (PF4), autoimmune responses (granzyme B, perforin), and abnormal metabolism (arachidonic acid pathways); aid in monitoring patient health; and improve therapeutics (experimental phosphatidylcholine therapy has been shown to result in an improvement in intestinal condition).
Despite the enormous progress of proteomics and lipidomics in recent years and the development of new technologies, further research is needed to select some of the most sensitive and specific markers applicable in diagnosing and treating IBD.
炎症性肠病（IBD）的患病率正在上升，迄今为止，尚未开发出有效的治疗方法，该疾病的确切病因仍不清楚。然而，越来越多的蛋白质组学和脂质组学研究已经确定了某些蛋白质和脂质，它们可成功用于患者，以改善诊断和治疗监测。
我们专注于蛋白质和脂质在IBD诊断中的应用，包括克罗恩病（CD）和溃疡性结肠炎（UC）的鉴别、治疗监测、临床状态监测、复发可能性以及它们在新型靶向治疗中的潜力。
蛋白质和脂质谱分析可以：提高诊断标志物的可用性和应用；增进对IBD发病机制的理解，例如，多项研究表明血小板功能障碍（PF4）、自身免疫反应（颗粒酶B、穿孔素）和代谢异常（花生四烯酸途径）与之相关；有助于监测患者健康状况；并改善治疗效果（实验性磷脂酰胆碱治疗已显示可改善肠道状况）。
尽管近年来蛋白质组学和脂质组学取得了巨大进展以及新技术不断发展，但仍需要进一步研究，以筛选出一些最敏感和特异的标志物用于IBD的诊断和治疗。
